Systematic Literature Review of Real-world Evidence of Ceftolozane/Tazobactam for the Treatment of Respiratory Infections
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systematic Literature Review of Real-world Evidence of Ceftolozane/Tazobactam for the Treatment of Respiratory Infections
Authors
Keywords
-
Journal
Infectious Diseases and Therapy
Volume 10, Issue 3, Pages 1227-1252
Publisher
Springer Science and Business Media LLC
Online
2021-07-19
DOI
10.1007/s40121-021-00491-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Real-world experience with ceftolozane-tazobactam for multidrug-resistant gram-negative bacterial infections
- (2020) Sarah C.J. Jorgensen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical and Safety Evaluation of Continuously Infused Ceftolozane/Tazobactam in the Outpatient Setting
- (2020) Bruce M Jones et al. Open Forum Infectious Diseases
- Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study)
- (2020) Matteo Bassetti et al. Open Forum Infectious Diseases
- Clinical pharmacokinetics of ceftolozane and tazobactam in an obese patient receiving continuous venovenous haemodiafiltration: A patient case and literature review
- (2020) Ahmed Mahmoud et al. Journal of Global Antimicrobial Resistance
- Fluoroquinolone-based versus beta lactam-based regimens for complicated intra-abdominal infections: a meta-analysis of randomized controlled trials
- (2019) Michail N. Mavros et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Use of continuous infusion ceftolozane–tazobactam with therapeutic drug monitoring in a patient with cystic fibrosis
- (2019) Sarah Elizabeth Davis et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Incremental clinical and economic burden of suspected respiratory infections due to multi-drug-resistant Pseudomonas aeruginosa in the United States
- (2019) Y.P. Tabak et al. JOURNAL OF HOSPITAL INFECTION
- Bacteriophage Therapy of Ventilator-associated Pneumonia and Empyema caused by Pseudomonas aeruginosa
- (2019) Susan Maddocks et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
- (2019) Marin H Kollef et al. LANCET INFECTIOUS DISEASES
- Higher MICs (>2 mg/L) Predict 30-day Mortality in patients with Lower Respiratory Tract Infections Caused by Multidrug and Extensively Drug Resistant Pseudomonas aeruginosa Treated with Ceftolozane/Tazobactam
- (2019) O Rodríguez-Núñez et al. Open Forum Infectious Diseases
- 2281. Ceftolozane–tazobactam (C/T) Treatment Outcomes in Immunocompromised (IC) Patients with Multidrug-Resistant (MDR) Pseudomonas aeruginosa (PA) Infections
- (2019) Delaney E Hart et al. Open Forum Infectious Diseases
- 2286. Evaluating the Impact of Ceftolozane/Tazobactam on Clinical Outcomes in Patients with Multi-Drug-resistant Pseudomonas aeruginosa Pneumonia
- (2019) Matthew Mills et al. Open Forum Infectious Diseases
- Ceftolozane–tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa pneumonia in a patient receiving intermittent hemodialysis
- (2018) Mohammed A. Alessa et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients
- (2018) Morgan Hakki et al. INFECTION
- Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections
- (2018) Laura Escolà-Vergé et al. INFECTION
- Carbapenems versus alternative β-lactams for the treatment of nosocomial pneumonia: A systematic review and meta-analysis
- (2018) J. Nicholas O'Donnell et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Evidence of clinical response and stability of Ceftolozane/Tazobactam used to treat a carbapenem-resistant Pseudomonas Aeruginosa lung abscess on an outpatient antimicrobial program
- (2018) A. Stewart et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa
- (2018) Marc Xipell et al. Journal of Global Antimicrobial Resistance
- Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands
- (2018) Manuel Díaz-Cañestro et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- A systematic review of the association between delayed appropriate therapy and mortality among patients hospitalized with infections due to Klebsiella pneumoniae or Escherichia coli: how long is too long?
- (2018) Thomas P. Lodise et al. BMC INFECTIOUS DISEASES
- Ceftolozane/tazobactam for the treatment of serious P. aeruginosa infections: a multicenter nationwide clinical experience
- (2018) Matteo Bassetti et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
- (2018) George H Talbot et al. JOURNAL OF INFECTIOUS DISEASES
- Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study
- (2018) Jason C Gallagher et al. Open Forum Infectious Diseases
- Impact of Delayed Appropriate Antibiotic Therapy on Patient Outcomes by Antibiotic Resistance Status From Serious Gram-negative Bacterial Infections
- (2018) Nicole Gidaya Bonine et al. AMERICAN JOURNAL OF THE MEDICAL SCIENCES
- Systematic review finds that study data not published in full text articles have unclear impact on meta-analyses results in medical research
- (2017) Christine M. Schmucker et al. PLoS One
- Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections
- (2016) Juan José Castón et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam
- (2016) Alberto Hernández-Tejedor et al. INFECTION
- Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration
- (2016) Joseph L. Kuti et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-ResistantPseudomonas aeruginosa
- (2016) Stephen B. Vickery et al. PHARMACOTHERAPY
- Ceftazidime/Avibactam and Ceftolozane/Tazobactam in Treatment of Pulmonary Infections by Imipenem Resistant Pseudomonas aeruginosa
- (2016) Alina Iovleva et al. Open Forum Infectious Diseases
- Ceftolozane/Tazobactam: Outpatient Treatment of Gram-Negative Infections at Physician Office Infusion Centers (POICs)
- (2016) Ramesh V. Nathan et al. Open Forum Infectious Diseases
- Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-ResistantPseudomonas aeruginosa: Table 1.
- (2015) Michael S. Gelfand et al. CLINICAL INFECTIOUS DISEASES
- Comparative efficacy of antibiotics for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a systematic review and network meta-analysis
- (2015) H. Thom et al. CURRENT MEDICAL RESEARCH AND OPINION
- Diagnosis and management of community and hospital acquired pneumonia in adults: summary of NICE guidance
- (2014) S. Eccles et al. BMJ-British Medical Journal
- Hospital‐Acquired Pneumonia, Health Care–Associated Pneumonia, Ventilator‐Associated Pneumonia, and Ventilator‐Associated Tracheobronchitis: Definitions and Challenges in Trial Design
- (2010) Michael S. Niederman CLINICAL INFECTIOUS DISEASES
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started